

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims.**

1-41. **(Cancelled)**

42. **(Currently Amended)** A method of treating a patient having an injury to or a disorder of an eye, said injury or disorder comprising degeneration of a photoreceptor cell, said method comprising administering to a patient a polypeptide comprising amino acids 108 to 188 of SEQ ID NO:2, which includes the eight conserved cysteines at amino acids 108, 133, 139, 142, 143, 150, 186 and 188 in an amount sufficient to proliferate photoreceptor cells.

43. **(Previously Presented)** The method of claim 42, wherein the polypeptide is attached to a water soluble polymer.

44. **(Previously Presented)** The method of claim 43, wherein the water soluble polymer is polyethylene glycol.

45. **(Cancelled)**

46. **(Previously Presented)** The method of claim 42, wherein the polypeptide is administered as a sustained-release pharmaceutical composition.

47. **(Previously Presented)** The method of claim 42, wherein the polypeptide is administered as a topical pharmaceutical composition.

48. **(Previously Presented)** The method of claim 42, wherein the polypeptide is administered as an oral pharmaceutical composition.

49. **(Previously Presented)** The method of claim 42, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

50. **(Previously Presented)** The method of claim 42, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

51. **(Previously Presented)** The method of claim 50, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

52. **(Previously Presented)** The method of claim 42, wherein the polypeptide comprises amino acids 80 to 202 of SEQ ID NO:2.

53. **(Previously Presented)** The method of claim 52, wherein the polypeptide is attached to a water soluble polymer.

54. **(Previously Presented)** The method of claim 53, wherein the water soluble polymer is polyethylene glycol.

55. **(Canceled)**

56. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as a sustained-release pharmaceutical composition.

57. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as a topical pharmaceutical composition.

58. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as an oral pharmaceutical composition.

59. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

60. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

61. **(Previously Presented)** The method of claim 60, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

62. **(Previously Presented)** The method of claim 42, wherein the polypeptide comprises amino acids 9 to 396 of SEQ ID NO:2.

63. **(Previously Presented)** The method of claim 62, wherein the polypeptide is attached to a water soluble polymer.

64. **(Previously Presented)** The method of claim 63, wherein the water soluble polymer is polyethylene glycol.

65. **(Canceled)**

66. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as a sustained-release pharmaceutical composition.

67. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as a topical pharmaceutical composition.

68. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as an oral pharmaceutical composition.

69. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

70. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

71. **(Previously Presented)** The method of claim 70, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

72. **(Canceled)**

73. **(Previously Presented)** The method of claim 42, wherein the injury or disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.

74. **(Previously Presented)** The method of claim 52, wherein the injury or disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.

75. **(Previously Presented)** The method of claim 62, wherein the injury or disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.

76. **(Canceled)**